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Abstract
Background Parathyroid hormone (PTH) has been asso-
ciated with anemia only in dialysis patients with severe
hyperparathyroidism. Whether an association between
PTH and hemoglobin also exists in patients with chronic
kidney disease not on dialysis (CKD-patients) is still
unclear. In this study we evaluated the association between
PTH and hemoglobin in CKD-patients without severe
secondary hyperparathyroidism.
Methods Hospitalized patients and outpatients (N = 979)
were retrospectively evaluated and categorized according
to PTH quartile and serum hemoglobin (\12.0, \11.0,
\10.0 g/dl). Gender, diabetes, glomerular filtration rate
(GFR), hemoglobin, PTH, markers of mineral metabolism,
inflammation, iron status and nutrition were variables of
adjustment in univariate and multivariate analysis.
Results An inverse association (p = 0.001) was observed
between PTH and hemoglobin in patients as a whole, in
diabetics, and in patients with GFR B60 ml/min. PTH was
the single predictor of low hemoglobin in patients as a
whole (unstandardized beta -2.12; p = 0.005), in diabet-
ics (unstandardized beta -8.86; p = 0.007) and in patients
with GFR B60 ml/min (unstandardized beta -2.52;
p = 0.006). For each increase of quartile of PTH the risk of
having hemoglobin level \10.0 mg/dl was more than
doubled [hazard ratio (HR) 2.79, 95 % confidence interval
(CI) 2.00–3.88; p = 0.001]. The receiver operating char-
acteristic curve showed that PTH C122 pg/ml had 67 %
sensitivity and 75 % specificity in predicting hemoglobin
level\10.0 g/dl with area under the curve of 0.758 (95 %
CI 0.73–0.78).
Conclusions This study shows a significant inverse
association between PTH and hemoglobin levels across the
whole spectrum of non-dialysis CKD and a doubled risk of
having serum hemoglobin\10.0 mg/dl in the absence of
severely deranged PTH concentration. These findings may
have clinical relevance in ascertaining the cause of unex-
plained low hemoglobin levels in CKD-patients.
Keywords Parathyroid hormone  Hemoglobin 
Anemia  Chronic kidney disease
Introduction
In past experimental studies it was observed that synthesis
of endogenous erythropoietin, formation of erythroid pro-
genitors, and survival of red cells were reduced by a high
PTH [1–3]. Similarly, negative effects of very high serum
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levels of PTH on serum hemoglobin were observed in
patients on dialysis. In fact, improved serum concentration
of hemoglobin, need for lower doses of erythropoietin
stimulating agents and reduced fibrosis of bone marrow
were attained after either better control of secondary
hyperparathyroidism or parathyroidectomy [4–12].
Whether the association between PTH and hemoglobin
exists in patients with chronic kidney disease not on dial-
ysis (CKD-patients) has been little evaluated. The aim of
the present study was to assess whether there is an asso-
ciation between PTH and hemoglobin in CKD-patients
without severely deranged serum PTH concentrations and
who did not undergo previous therapy with erythropoietin
stimulating agents and/or vitamin D. Confirmation of this
association may have clinical relevance in assessing the
cause of unexplained low hemoglobin level in CKD-
patients.
Subjects and methods
This is a retrospective observational cohort study per-
formed in hospitalized patients and outpatients who had
been referred to a single Nephrology Unit from year 2002
to year 2009. The study was approved by the local Insti-
tutional Review Board.
Criteria for evaluation were age [18 years, at least
6 months of follow-up prior to the collection of pertinent
data, and two assays of PTH and hemoglobin performed by
the same laboratory. Exclusion criteria were: stage 5
chronic kidney disease requiring dialysis treatment, rapidly
progressive glomerulonephritis, polycystic kidney disease,
past or recent therapy with iron, erythropoietin stimulating
agents, or vitamin D sterols, presence of bleeding and/or
need for blood transfusion in the previous medical history,
and current treatment with warfarin that may cause unap-
parent blood loss.
Patients underwent full clinical examination, medical
history and routine blood chemistry. Diabetic patients were
defined as those on regular use of insulin or oral hypo-
glycemic drugs. Patient characteristics and routine chem-
istry were stratified according to quartiles of serum PTH
concentration. Presence of anemia was established on the
basis of three cut-off levels of serum hemoglobin; the first
cut-off was serum hemoglobin\12.0 g/dl, that has been
indicated as the lower normal level of hemoglobin for the
diagnosis of anemia in adult females with CKD [13]; we
arbitrarily extended this level to the male population. The
second cut-off was serum hemoglobin\11.0 g/dl, that is
regarded as the threshold for starting erythropoietin stim-
ulating agents in CKD-patients [14–16]. The third cut-off
was serum hemoglobin \10.0 g/dl, since hemoglobin
concentration of 10.0 g/dl has recently been suggested as
the lowest adequate level of hemoglobin in European
CKD-patients [17].
Analyses were performed on patients as a whole, and on
two subgroups: those with diabetics, and those with glo-
merular filtration rate (GFR) B60 ml/min. The subgroup
analysis was done since previous studies which have
evaluated the epidemiology of anemia associated with
chronic renal insufficiency and in diabetics [18–20] did not
take into account levels of PTH as a potential factor
responsible for reduced hemoglobin levels.
Blood samples were collected in the morning in fasting
state. Variables assessed were: glucose, urea, hemoglobin,
iron, ferritin, transferrin saturation (TSAT %), calcium,
phosphorus, intact parathyroid hormone (i-PTH), 24/h
urinary protein excretion, alkaline phosphatase, uric acid,
homocysteine, C-reactive protein (hs-CRP), triglycerides,
total cholesterol, high-density lipoprotein cholesterol
(HDL-cholesterol) and low-density lipoprotein cholesterol
(LDL-cholesterol).
Body mass index (BMI) was computed as weight (in
kilograms) divided by the square of the height (in meters).
Kidney function was assessed by 24/h-measured creatinine
clearance and reported as GFR. i-PTH was assayed by the
chemiluminescent immunometric method. Hs-CRP was
assayed by the immunoturbidimetric method. LDL-cho-
lesterol was calculated using the Friedewald equation.
TSAT was calculated dividing serum iron and total iron-
binding capacity, multiplied by 100.
Statistics
Continuous data are reported as median and interquartile
range. Frequency data are given as numbers and percent-
ages. Normal distribution of data was tested using the
Shapiro–Wilk test. Skewed variables were log-transformed
to improve normality in regression models. Univariate
correlations between continuous variables were analyzed
by Pearson’s test. Variables significantly associated with
hemoglobin at univariate analysis were used for multivar-
iate linear regression. Hemoglobin concentration was used
as the dependent variable in multivariate linear regression
models to identify factor(s) independently associated with
hemoglobin in patients as a whole, in those with diabetes,
and in those with GFR B60 ml/min. Presence of multi-
collinearity was checked and collinear variables were
excluded from multivariate analysis. Logistic regression
was used to predict to what extent incremental quartiles of
PTH increased the risk of having serum hemoglobin levels
\10.0 mg/dl. A receiver operating characteristic (ROC)
curve was generated to assess sensitivity and specificity of
PTH in predicting serum hemoglobin levels\10 mg/dl.
Values of p\ 0.05 were considered as statistically
significant.
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Data were analyzed with the Statistical Package for the
Social Sciences (SPSS) version 19 (Chicago, IL, USA).
Results
The initial number of screened patients was 1,093, of
which 114 were non eligible. Causes for ineligibility were:
chronic lung disease (n = 35), inability to give reliable
personal medical history (n = 30), severe liver disease
(n = 25), chronic therapy with nonsteroidal anti-inflam-
matory drugs (NSADs) (n = 15), and hemorrhoids
(n = 9). The final analysis was performed on data of 979
patients.
The primary renal diagnoses were: hypertensive
nephropathy (26 %), glomerulonephritis (16 %), diabetes
(11 %), ischemic nephropathy (6 %), minor urinary
abnormalities (4 %), interstitial nephritis (4 %), and CKD
of unknown cause (34 %). The majority of the study
population did not have severe derangement of PTH levels
(upper normal limit for our laboratory 75 pg/ml); in detail,
PTH[150 pg/ml was found in 207 (21 %) patients while
PTH[1,000 pg/ml was found in 3 (0.3 %) patients.
Clinical characteristics and biochemistry of patients
were evaluated in aggregate and according to quartiles of
PTH; the results are shown in Table 1. Patients in the
highest quartile of PTH were more likely to have reduced
GFR, serum albumin concentration, total cholesterol and
LDL-cholesterol; in addition, they were more likely to
have increased serum concentration of fibrinogen and
homocysteine and 24/h urinary protein excretion.
At univariate analysis serum hemoglobin was signifi-
cantly (p = 0.001) associated with: age (r = -0.21),
gender (r = -0.20), diabetes (r = -0.27), PTH
(r = -0.42), serum calcium (r = -0.47), serum phos-
phorus (r = 0.60), GFR (r = 0.32), transferrin saturation
(r = 0.19), CRP (r = -0.34), homocysteine (r = -0.26),
serum albumin (r = 0.49), and serum cholesterol
(r = 0.24); serum hemoglobin was not associated with
ferritin (r = 0.10; p = 0.08) or BMI (r = 0.04; p = 0.30).
The inverse association between PTH and hemoglobin is
shown in Fig. 1. A significant association was observed in
patients as a whole (r = -0.459; p = 0.000), in patients
with serum hemoglobin \12.0 g/dl (r = -0.176;
p = 0.000), and in patients with serum hemoglobin
[12.0 g/dl (r = -374; p = 0.01).
The results of multivariate linear regression analysis in
patients as a whole are reported in Table 2. There was
collinearity of fibrinogen and homocysteine with CRP; thus
fibrinogen and homocysteine were excluded from the final
model. In the final model, high PTH was the only signifi-
cant predictor of low hemoglobin (unstandardized coeffi-
cients beta -2.12; p = 0.005). Of interest, we found a
significant interaction between log-PTH and GFR
(p = 0.006); despite this interaction, PTH remained the
single significant (p = 0.000) predictor of low hemoglobin.
The association between PTH and hemoglobin levels in
patients as a whole is reported in Table 1. There was an
inverse association between PTH and hemoglobin levels
(p = 0.001). In logistic regression, for each increase of
quartile of PTH the risk of having hemoglobin levels
\10.0 mg/dl was more than doubled [hazards ratio (HR)
2.79, 95 % confidence interval (CI) 2.00–3.88, p = 0.001].
The ROC curve is shown in Fig. 2. PTH C122 pg/ml had a
sensitivity of 67 % and a specificity of 75 % in predicting
hemoglobin level\10.0 g/dl with area under the curve of
0.758 (95 % CI 0.73–0.78).
Results of multivariate linear regression analysis in
diabetics and in patients with GFR B60 ml/min are
reported in Tables 3 and 4, respectively. The collinearities
found in patients as a whole were found also in diabetic
patients and in those with GFR B60 ml/min; for these
subgroups, therefore, the final multivariate linear regres-
sion model had similar variables as for the final model of
patients as a whole. High PTH was confirmed as the single
predictor of low serum hemoglobin concentration in dia-
betic patients (unstandardized coefficients beta -8.86,
p = 0.007) and in patients with GFR B60 ml/min
(unstandardized coefficients beta -2.52, p = 0.006).
The majority of anemic patients were found in the
highest quartile of PTH whatever the level of hemoglobin
used for the definition of anemia (Table 1). The percent-
age of anemic patients was even higher in diabetics and in
patients with GFR B60 ml/min. Indeed, percentage of
anemic diabetic patients was 62, 37, and 21 % at levels of
hemoglobin\12.0,\11.0, and\10.0 g/dl. The percent-
age of anemic patients with GFR B60 ml/min was 84, 43,
and 31 % at levels of hemoglobin \12.0, \11.0,
and\10.0 g/dl.
Discussion
Parathyroid hormone has been associated to anemia in the
past. However, this association was ascertained in patients
on chronic dialysis treatment with long-lasting secondary
hyperparathyroidism and very high serum concentration of
PTH [4–12]. In the present study, the inverse association
between PTH and serum hemoglobin concentration was
observed across the whole spectrum of non-dialysis CKD
without severe secondary hyperparathyroidism. This find-
ing may be relevant in clinical practice.
Serum concentrations of PTH that may be regarded as
not relevant in everyday care of CKD-patients were a
predictor of low hemoglobin concentration. The progres-
sion of PTH from the 1st to the 4th quartile was associated
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Fig. 1 Association between PTH and hemoglobin serum concentration in patients as a whole, and in anemic (serum hemoglobin\12.0 g/dl) and
non-anemic patients (serum hemoglobin C12.0 g/dl)
Table 2 Multiple regression
analysis with serum hemoglobin
concentration as the dependent
variable in patients as a whole
Due to presence of collinearity
log-ferritin, fibrinogen,
homocysteine, BMI were
excluded from the final model
GFR glomerular filtration rate





a Log transformed variable
Unstandardized coefficients B Std. error t p 95.0 % confidence
interval for B
Lower Upper
Age -0.01 0.02 -0.79 0.433 -0.05 0.02
Gender -0.77 0.48 -1.60 0.116 -1.74 0.20
Diabetes -0.11 0.48 -0.22 0.824 -1.08 0.87
GFR 0.00 0.01 0.07 0.947 -0.02 0.02
PTHa -2.12 0.73 -2.91 0.005 -3.59 -0.66
Serum calcium -0.02 0.41 -0.05 0.957 -0.84 0.79
Serum phosphorus -0.50 0.33 -1.54 0.131 -1.16 0.16
TSAT 0.03 0.03 0.98 0.332 -0.03 0.08
Albumin 0.17 0.50 0.35 0.731 -0.84 1.18
Cholesterol 0.01 0.01 2.00 0.051 0.00 0.02
PCRa -0.57 0.66 -0.86 0.395 -1.89 0.76
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to a progressive significant decrease of hemoglobin con-
centration. The increase of each PTH quartile was associ-
ated to more than a doubled risk of having hemoglobin
levels\10.0 mg/dl.
The association between PTH and hemoglobin was
independent of factors that are commonly related to anemia
in dialysis patients; age, gender, iron status, biomarkers of
inflammation and nutrition were, in fact, not predictors of
hemoglobin concentration. Interestingly, the negative
association of PTH with hemoglobin was independent of
reduced renal function, indicating that PTH is a marker of
low hemoglobin independently of level of GFR.
The data observed in the present study are different from
those of previous published reports. In CKD-patients who
had been evaluated for a community-based screening pro-
gram a significant positive association between PTH and
hemoglobin was observed only in diabetics [21]. In the
present study, we observed a negative association between
PTH and hemoglobin levels both in diabetics and in
patients with GFR B60 ml/min. These conflicting data may
be possibly explained by the following factors. In the
community screening study, diabetics represented half of
study population; the majority of the participants were
female (69.2 %) and were 70 years old; all participants had
GFR \60 ml/min; cancer was present in 20 % of the
population; iron parameters were not assessed; biochemical
parameters inclusive of PTH and hemoglobin were assayed
in several laboratories and not in standardized conditions of
blood sampling and fasting state.
The percentage of anemic patients recorded in the
present study should be highlighted. Indeed, categorizing
as anemic our patients on the basis of three cut-off levels of
hemoglobin, anemia was relevant whatever hemoglobin
level was taken into the account. Indeed, in the whole
cohort, the percentage of anemic patients ranged from 41 to
11 % considering as cut-off the levels of hemoglobin lower
than 12.0, 11.0 and 10.0 g/dl. In addition, the percentage of
patients with anemia was always higher in patients in the
highest quartile of PTH whatever the level of serum
hemoglobin concentration used for the definition of
anemia.
In our opinion, the data of the present study may be
clinically relevant in ascertaining the cause of unexplained
low hemoglobin level in CKD-patients without severe
secondary hyperparathyroidism. In the presence of reduced
serum hemoglobin concentration in patients with
Fig. 2 Receiver operating characteristic curve for sensitivity and
specificity of PTH in predicting serum hemoglobin concentration
\10.0 mg/dl in patients as a whole
Table 3 Multiple regression
analysis with serum hemoglobin
concentration as the dependent
variable in diabetics (N = 165)
Due to presence of collinearity
log-ferritin, fibrinogen,
homocysteine, BMI were
excluded from the final model
GFR glomerular filtration rate





a Log transformed variable
Unstandardized
coefficients B
Std. error t p 95.0 % confidence interval for B
Lower Upper
Age -0.10 0.08 -1.32 0.244 -0.31 0.10
Gender -0.65 1.09 -0.60 0.578 -3.45 2.15
GFR -0.01 0.02 -0.66 0.536 -0.06 0.04
PTHa -8.86 2.00 -4.43 0.007 -14.00 -3.72
Serum calcium 2.58 0.95 2.71 0.042 0.13 5.02
Serum Phosphorus -0.43 0.52 -0.83 0.445 -1.77 0.91
TSAT -0.01 0.03 -0.26 0.809 -0.08 0.07
Albumin -3.49 1.20 -2.91 0.033 -6.58 -0.41
Cholesterol 0.03 0.01 2.68 0.044 0.00 0.05
PCRa 2.26 1.28 1.77 0.138 -1.03 5.55
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biomarkers of inflammation and nutrition, the rational
therapeutic option is to initiate therapy with erythropoietin
stimulating agents. On the basis of data observed in the
present study, therapy with erythropoietin stimulating
agents would have been started in 20 % of patients even
using the most restrictive level of serum hemoglobin (e.g.
hemoglobin\10.0 g/dl). More likely it should be advisable
to take into the account the serum PTH even when its
concentration seems not severely deranged. In conjunction
to PTH assay the serum vitamin D assay should also be
taken into account, that has been found to be associated to a
decrease of hemoglobin and presence of anemia in CKD-
patients [22].
The present study has several limitations. The design
does not allow to establish causality but only an association
between PTH and hemoglobin levels. We were also unable
to determine the exact mechanisms explaining the associ-
ation between PTH and serum hemoglobin levels. We
cannot completely rule out residual confounding, although
we adjusted for the common potential explanatory factors.
Vitamin D levels were not assessed. Despite these limita-
tions, our study has the strength of having examined a large
population of adults with different degrees of CKD in a
real-world clinical practice setting. Importantly, the
patients did not receive previous erythropoietin stimulating
agents or vitamins D; therefore the association between
PTH and hemoglobin was evaluated without the con-
founding effects of these therapies.
Additional interventional studies are mandatory both to
confirm the association between PTH and hemoglobin, and
to assess whether better control of serum PTH may
improve serum level of hemoglobin in CKD-patients.
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